Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

As the complexity and need for cancer care services continue to grow, time to treatment initiation (TTI) has been increasing across cancer types. Presently there are no comprehensive analyses ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

LLMs demonstrated high accuracy in matching brand and generic names (GPT-4o: 97.38% for brand, 94.71% for generic, P < .01). However, they showed significant inconsistencies in word association tasks.

Frustrations regarding the costs and difficulties with parking at hospitals is a common concern voiced by patients, families, and healthcare providers. Transportation barriers to receiving cancer care ...

Background: Treatment options for pts with R/M SGC are limited. Responses to chemotherapy (CT) are low with high toxicity and responses to immune checkpoint inhibition (ICI) are <10%. Pemetrexed (PTX) ...

With that background, Birken et al 5 aimed to better understand the interplay between oncology and primary care in the follow-up of cancer survivors. The authors mined their electronic health record ...

The data set consisted of 3,106 glioblastoma tumor samples, of which 571 were from patients treated with bevacizumab. The majority were males (65%) and older than 60 years. Median survival was 17.5 ...

Background: Amivantamab is a bispecific antibody that was granted accelerated approval by the FDA in May 2021 for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor ...

Background: Interim results of the randomized phase II trial of neoadjuvant tislelizumab +/- oral APL-1202 (nitroxoline) revealed promising pathological complete response (pCR) rates and met ...

Distress and isolation frequently affect individuals with cancer and oncology care providers. Both oncology care teams and patient communities play a crucial role in offering support during ...